Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Telcagepant failure is a headache for Merck (and perhaps Pfizer) but a break for others

This article was originally published in Scrip

Executive Summary

While Merck’s latest job cuts were at the fore of its Q2 update (, 1 August 2011), the discontinuation of its promising Phase III acute migraine therapy telcagepant is also notable and will add to the company’s woes. It had been expected to become an important treatment option for migraineurs and compete with the triptan class, the standard of care for the past 20 years. Without telcagepant, the acute migraine market will contract, leaving the prophylactic treatment of migraine as the biggest opportunity for developers.


Related Content

Migraine Drug Atogepant Delivers Good News When Allergan Needs It Most
Biohaven Posts Positive Migraine Results, But Investors Are Wary
Allergan Touts Ubrogepant Phase III Success, But Liver Tox Concerns Overhang
Best-In-Class Or First-In-Class: CGRP Inhibitors Line Up To Win The Migraine Market


Related Companies




Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts